| |
| |
 |
| |
|
|
| |
While all cancers display uninterrupted cell proliferation, their heterogeneity often makes them difficult to treat. Given these characteristics, Plexxikon is pursuing a number of drug targets for the treatment of different cancers.
PLX4032 is Plexxikon's lead program in oncology, now in a Phase 1 clinical trial. This drug candidate selectively targets the B-RafV600E gene, a mutation that has been shown to drive certain cancers. This pivotal mutation occurs only in tumor cells and affects approximately 70% of malignant melanomas, as well as a large number of colorectal and thyroid cancers.
Since September 2006, Plexxikon has been co-developing PLX4032 with Roche. Additionally, the two companies are developing a diagnostic test to select patients who carry the B-RafV600E mutation and would be likely responders to this agent.
Plexxikon has developed a portfolio of novel drug candidates designed to treat diseases primarily driven by osteoclasts, macrophages and mast cells — all cells of the immune system. These cell types drive certain cancers and inflammatory diseases. The company is developing
a candidate for the treatment of osteolytic metastatic
disease in breast cancer, multiple myeloma, as well as
less severe rheumatoid arthritis.
 Oncology: Melanoma and Colorectal Cancer Program Fact Sheet
Oncology: Osteolytic Metastatic Disease Program Fact Sheet
|
|
| |
|
|
|
|
| |
| | | | | | |
| | | | | | | | |
| © 2007 Plexxikon Inc. | Site design by |
| |
|
|
